Bioventix PLC, a UK company known for developing high-quality antibodies used in medical tests, has reported a small dip in its yearly performance. For the year ending June 30, 2025, the company’s revenue fell by 4% to £13.1 million. Profit before tax also dropped slightly, from £10.6 million last year to £10.1 million. By the end of the financial year, Bioventix had £5.1 million in cash, compared to £6 million the year before.
The company said its performance was hurt by difficulties in the Chinese market. China’s government has been pushing for lower healthcare costs, leading to tighter pricing on medical testing supplies. This policy has affected both Bioventix’s Chinese customers and its Western clients doing business there.
Despite these challenges, Bioventix’s main vitamin D antibody products did well, bringing in £6.6 million in sales, a 12% increase from the previous year. However, other parts of the business struggled. Sales of biotins and biotin blockers dropped 40%, progesterone sales were down 16%, and estradiol fell 19%.
The company announced a second interim dividend of 80 pence per share, bringing the total dividend for the year to 150 pence. That’s just below the 155 pence per share paid out last year.
Looking ahead, Bioventix expects similar conditions over the next year, with pressure continuing in its older product lines. The company said it expects a small drop in revenue for 2025-2026 but sees strong potential in newer areas like neurology and troponin testing, both of which are key in diagnosing brain and heart conditions.
There was a bright spot in the results: the neurology division showed impressive growth. Sales from its Tau and neuro SMA antibodies jumped from £155,000 last year to £605,000 this year, a fourfold increase.
While the company faces near-term challenges, Bioventix believes that innovation in new testing areas could help it return to growth in the coming years.
